A Phase I Study of Batracylin (NSC 320846) in Subjects With Solid Tumours and Lymphomas.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Daniquidone (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- 05 Dec 2019 Biomarkers information updated
- 18 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov. (NCT00450502)
- 18 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov. (NCT00450502)